Jump to ContentJump to Main Navigation
Show Summary Details

Roth, Christian

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Cohen, Pinhas / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Toppari, Jorma

Editorial Board Member: Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / Hiort, Olaf / LaFranchi, Stephen H. / Lanes M. D., Roberto / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Zadik, Zvi

IMPACT FACTOR 2015: 0.912

SCImago Journal Rank (SJR) 2015: 0.493
Source Normalized Impact per Paper (SNIP) 2015: 0.600
Impact per Publication (IPP) 2015: 0.955

See all formats and pricing


Select Volume and Issue


30,00 € / $42.00 / £23.00

Get Access to Full Text

The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism

Shuwen Hu1 / Zidi Xu1 / Jie Yan1 / Min Liu1 / Bing Sun1 / Wenjing Li1 / 1, 2

1National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education Endocrine and Genetic Metabolic Center, Beijing Children’s Hospital Affiliated to Capital Medical University, Beijing 100045, China

2Department of Endocrinology, Beijing Children’s Hospital Affiliated to Capital Medical University, Fuxingmenwai Nanlishi Road 56, Beijing 100045, China

Corresponding author: Yanmei Sang, Department of Endocrinology, Beijing Children’s Hospital Affiliated to Capital Medical University, Fuxingmenwai Nanlishi Road 56, Beijing 100045, China

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 25, Issue 11-12, Pages 1119–1122, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2012-0224, October 2012

Publication History

Published Online:


Objective: To study the treatment effect and safety of diazoxide on patients with congenital hyperinsulinism (CHI).

Research design and methods: A total of 44 patients who have been hospitalized to our hospital and used diazoxide as a trial after diagnosis of CHI were chosen as research subjects. The clinical data of the patients were analyzed, and the treatment effects and safety of diazoxide on CHI were evaluated.

Results: In the 44 patients studied, the blood glucoses of 36 cases recovered to normal level after using diazoxide, indicating that the 36 patients respond to the treatment of diazoxide. Eight cases still showed severe hypoglycemia after using diazoxide for 10 days, which indicated that the eight patients were unresponsive to diazoxide treatment. Eighteen patients suffered the side effect of fluid retention, and 12 patients suffered transient gastrointestinal reactions.

Conclusion: Diazoxide is a first-line treatment of CHI with high safety. Most of the patients with CHI were responsive to diazoxide treatment. Diazoxide should be used as a trial immediately after CHI diagnosis was made.

Keywords: congenital hyperinsulinism; diazoxide; side effect

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Paul J. Rozance
Current Opinion in Endocrinology & Diabetes and Obesity, 2014, Volume 21, Number 1, Page 45

Comments (0)

Please log in or register to comment.